MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuromelanin"

  • 2023 International Congress

    Comparing neuromelanin intensity estimation techniques for Parkinson’s disease image analysis

    V. Madge, V. Fonov, A. Bailey, A. Dagher, E. Fon, R. Postuma, DL. Collins (Montréal, Canada)

    Objective: The objective of this study is to compare robust neuromelanin (NM) substantia nigra pars compacta (SN) and locus coeruleus (LC) quantification techniques captured in…
  • 2022 International Congress

    Blaming neuromelanin for Parkinson’s disease: time-dependent tyrosinase overexpression drives endogenous synucleinopathy in non-human primates

    J. Lanciego, J. Chocarro, A. Fajardo-Serrano, A. Vazquez, AI. Rodriguez-Perez, J. Labandeira-Garcia, M. Vila, A. Rico (Pamplona, Spain)

    Objective: Development and characterization of a novel non-human primate model of Parkinson’s disease based on the AAV-mediated forced expression of human tyrosinase Background: Although neuromelanin…
  • 2022 International Congress

    Characterization of neuromelanin MRI as a potential Parkinson’s Disease biomarker in a multi-site longitudinal study

    M. Ingalhalikar, H. Pham, L. Bracoud, RM. Hutchison, K. Evans, T. Dam, M. Sampat, J. Schaerer, C. Conklin, J. Suhy, D. Scott (San Mateo, USA)

    Objective: To investigate (1)longitudinal change and (2)cross-sectional vendor differences in neuromelanin MRI in substantia nigra pars compacta(SNpc) in PD patients. Background: Neuromelanin(NM) MRI is a…
  • 2022 International Congress

    Brain effects of high-intensity exercise on the dopamine system in individuals with Parkinson’s disease

    S. Tinaz, B. de Laat, G. Stanley, J. Hoye, J. Key, M. Hespeler, J. Ligi, Y. Huang, N. Nabulsi, E. Morris (New Haven, USA)

    Objective: We used PET imaging with 18F-FE-PE2I to quantify dopamine transporter availability and neuromelanin (NM)-MRI to measure the NM content in the substantia nigra (SN)…
  • 2022 International Congress

    Optimization of a neuromelanin MRI protocol for use in a longitudinal study of substantia nigra depigmentation in early Parkinson’s Disease (the InsIght-PD study)

    T. Hayat, S. Pszczolkowski, Y. Xing, C. Tench, P. Morgan, J. Evans, D. Auer (Nottingham, United Kingdom)

    Objective: To optimize a neuromelanin-MRI (NM-MRI) protocol for robust and timely change analysis; and acquire serial NM-MRI data in controls and early Parkinson’s Disease (PD),…
  • MDS Virtual Congress 2021

    VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

    J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila (Barcelona, Spain)

    Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…
  • MDS Virtual Congress 2021

    Age-dependent multisystem parkinsonian features in a novel neuromelanin-producing transgenic mouse model

    N. Peñuelas, A. Laguna, M. Gonzalez-Sepulveda, LL. Miquel-Rio, N. Benseny-Cases, H. Xicoy, J. Compte, A. Nicolau, M. Lorente-Picón, E. álvarez-Marimon, J. Romero-Giménez, A. Parent, T. Cuadros, F. Cacho-Nerin, J. Cladera, A. Bortolozzi, I. Carballo-Carbajal, M. Vila (Barcelona, Spain)

    Objective: We aim to characterize the consequences of age-dependent intracellular neuromelanin accumulation in catecholaminergic neuronal populations to understand the relationship between this process and the…
  • MDS Virtual Congress 2021

    Longitudinal changes in nigral neuromelanin in early, levodopa-treated Parkinson’s disease

    K. Hwang, J. Langley, N. Kurra, S. Factor, X. Hu, D. Huddleston (Atlanta, USA)

    Objective: To assess longitudinal changes in neuromelanin (NM) content in the substantia nigra compacta (SNc) and its lateral-ventral subregion in Parkinson’s disease (PD). Background: NM-sensitive…
  • MDS Virtual Congress 2021

    Does neurodegeneration of the noradrenergic locus coeruleus follow a spatial gradient in Parkinson’s disease?

    C. Madelung, D. Meder, S. Fuglsang, V. Boer, E. Petersen, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

    Objective: To map degeneration of the locus coeruleus in Parkinson’s disease in-vivo using ultra-high field MRI. Background: Parkinson’s disease (PD) causes degeneration of dopaminergic neurons…
  • MDS Virtual Congress 2020

    L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production

    S. Martin, V. Jones, J. Taylor, S. Lane, J. Ehlting, A. Helton, P. Walter (Victoria, BC, Canada)

    Objective: Naturally-occuring quantities of in vivo neuromelanin (NM) are low, and the collection of NM from tissue involves laborious extraction and isolation. Thus, in vitro…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley